Premier Biomedical, Inc. Announces Next Phase of Laboratory Testing of its Anti-Cancer Therapy
ST. PETERSBURG, Fla., March 28, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) (http://www.premierbiomedical.com/) today announced that it has advanced its pre-clinical testing of its extracorporeal-treatment methodology for use against cancer from test tubes to mice. These tests are being conducted by academic researchers at The University of Texas at El Paso (UTEP) under direction of Dr. Mitchell S. Felder of Premier Biomedical (PBI).
PBI and UTEP are ahead of schedule by over one (1) year. Typical laboratory tests take up to 2 years before providing the requisite positive results to move to this next phase of study. However, lab tests have demonstrated the successful removal of picogram (one trillionth of a gram) quantities of cytokines from a heterogeneous mixture. Subsequently, the methodology being tested has had extremely successful laboratory results in the killing of multiple tumors in test tubes that are dependent on these same cytokines for survival. With no anticipated side-effects because of the extracorporeal process, the results could pave the way to the efficacious treatment of cancer treatment in humans.
Premier Biomedical, Inc. CEO William A. Hartman indicated that they expect the results from these studies to provide new therapeutic strategies into treating certain forms of cancer during the third quarter of 2013, but other diseases including Alzheimer's Disease and Traumatic Brain Injury are progressing as well. If the results prove successful, use of Premier Biomedical's proprietary technology will be developed further with the goal of initiating clinical studies for these diseases in humans.
More information regarding Premier Biomedical, Inc.'s proprietary and novel cancer therapy can be found at Premier Biomedical, Inc.'s website at www.premierbiomedicalinc.com.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." www.premierbiomedicalinc.com
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
William A. Hartman, CEO
SOURCE Premier Biomedical, Inc.